HomeMost PopularInvestingMoleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

Actionable Trade Ideas

always free

Study Enrollment Completed for Moleculin’s Lead Candidate, Annamycin

Moleculin Biotech, Inc. (MBRX), a clinical-stage company, announced the completion of enrollment for the phase II portion of its early-to-mid-stage clinical program for its lead candidate, Annamycin. The phase IB/II MB107 study is evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases in the United States.

Annamycin is a next-generation anthracycline that has shown effectiveness without cardiotoxicity in early-stage clinical studies. Moleculin is currently developing Annamycin for the treatment of acute myeloid leukemia (AML) and STS lung metastases, with potential use in other indications.

Top-Line Results Expected in Q4 2023

Moleculin expects to release top-line results from the phase II portion of the MB107 study in the fourth quarter of 2023.

Stock Soars in Response to News

Following the announcement, the company’s stock rose approximately 10% on Thursday. Year to date, shares of Moleculin have declined 60.4% compared to a 14.8% fall in the medical, biomedical, and genetics industry.

Zacks Investment Research
Image Source: Zacks Investment Research

Evaluating Annamycin in STS Lung Metastases

The phase II portion of the study aims to evaluate the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung metastases who are suitable for chemotherapy.

Patients treated with Annamycin, who demonstrate stable disease at the time of study discontinuation, will continue to be followed for progression-free response and overall survival.

Promising Potential of Annamycin

Although the data available from the MB107 study is not yet sufficient due to ongoing follow-up examinations, Moleculin’s management believes that the median progression-free response is over 60% based on the data demonstrated to date. This is notable considering the subjects in the study have received multiple chemotherapy regimens.

Annamycin currently holds both Fast Track Status and Orphan Drug Designation from the FDA for the treatment of soft tissue sarcoma and Orphan Drug Designation in the relapsed or refractory AML indication.

Additional Studies Involving Annamycin

Moleculin is also evaluating Annamycin in combination with Cytarabine in the phase IB/II MB106 study for the treatment of subjects with AML as both first-line therapy and for those who are refractory to or have relapsed after induction therapy.

Zacks Rank and Stocks to Consider

Moleculin currently holds a Zacks Rank #3 (Hold).

Some better-ranked stocks in the overall medical sector include Dynavax Technologies (DVAX), Corcept Therapeutics (CORT), and Better Therapeutics (BTTX), each carrying a Zacks Rank #2 (Buy) at present.

In the past 30 days, the Zacks Consensus Estimate for Dynavax’s 2023 loss per share has narrowed from 24 cents to 23 cents. The estimate for Dynavax’s 2024 earnings per share is currently pegged at 3 cents. Year to date, shares of DVAX have risen by 29%.

Corcept’s 2023 earnings per share estimate has remained constant at 78 cents, and the estimate for 2024 earnings per share has also remained constant at 83 cents. Year to date, shares of CORT have climbed 57.3%.

Better Therapeutics’ 2023 loss per share estimate has remained constant at 98 cents, and the 2024 loss per share estimate has also remained constant at 80 cents. Year to date, shares of BTTX have fallen by 68.3%.

For the latest recommendations from Zacks Investment Research, you can download the free report on the 7 Best Stocks for the Next 30 Days.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.